Novo Nordisk & Eli Lilly and Company
21 shared events · Importance 5 · Last updated Apr 03, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
NewsDesk Dashboard
Regulatory
Novo Nordisk: Novo Nordisk agreed to lower prices for its obesity drug Wegovy, making it more accessible to United States — Medicare and United States — Medicaid recipients and those paying directly. The company's spokesperson declined to provide specific details on pricing changes.
Eli Lilly and Company: Eli Lilly and Company agreed to lower prices for its obesity drug Zepbound and will sell a starter dose for $299 a month, with additional doses up to $449, representing $50 reductions from current direct-to-patient prices. Its sales of Zepbound have tripled this year to over $9 billion.
Nov 06, 2025 · 6 articles
Business
Novo Nordisk: Novo Nordisk's CEO, Lars Fruergaard Jørgensen, is stepping down due to market challenges and a significant decline in its share price, impacting its leadership and market position in the obesity drug market.
Eli Lilly and Company: Eli Lilly and Company is a key competitor to Novo Nordisk in the obesity drug market, with its drug Zepbound surpassing Wegovy in US prescriptions, contributing to Novo Nordisk's market challenges.
May 16, 2025 · 7 articles
Business
Novo Nordisk: Novo Nordisk announced significant job cuts and a revised profit outlook due to increased competition and slowing sales of its key weight-loss and diabetes drugs. The company aims to simplify its structure and reallocate resources for future growth.
Eli Lilly and Company: Eli Lilly and Company is a major competitor to Novo Nordisk in the weight-loss and diabetes drug market, with its drug Zepbound gaining market share against Novo Nordisk's Wegovy.
Sep 10, 2025 · 6 articles
Business
Novo Nordisk: Novo Nordisk cut the price of its weight-loss drug Semaglutide in India to compete with Eli Lilly and prepare for generic competition, aiming to increase market share and accessibility.
Eli Lilly and Company: Eli Lilly and Company's drug Tirzepatide has been a strong competitor to Semaglutide in India, prompting Novo Nordisk to cut prices. Eli Lilly and Company has gained significant market share.
Nov 11, 2025 · 6 articles
Business
Novo Nordisk: Novo Nordisk launched its Wegovy pill in the United States, aiming to attract new consumers and regain market share in the competitive weight-loss drug market. This launch is expected to boost its fortunes after previous profit warnings and sliding shares.
Eli Lilly and Company: Eli Lilly and Company faces increased competition with Novo Nordisk's Wegovy pill launch, potentially impacting its market dominance in weight-loss drugs. Its shares fell following the announcement.
Jan 05, 2026 · 7 articles
Tech
Novo Nordisk: Novo Nordisk produces Semaglutide and Semaglutide, which are GLP-1 agonist drugs. The research indicates that patients regain weight quickly after discontinuing these medications, potentially impacting long-term sales and cost-effectiveness assessments by health systems.
Eli Lilly and Company: Eli Lilly and Company produces Tirzepatide and Tirzepatide, which are GLP-1 agonist drugs. The study's findings on rapid weight regain after stopping medication could affect the perceived long-term efficacy and market demand for their products.
Jan 08, 2026 · 6 articles
Business
Novo Nordisk: Novo Nordisk has shown a more aggressive M&A approach following recent CEO transitions and has been advised on recent deals, indicating its participation in the acquisition spree.
Eli Lilly and Company: Eli Lilly and Company is a leading pharmaceutical company with strong balance sheets, enabling it to be a major acquirer in the current M&A wave. It is also facing patent expirations on some of its blockbuster drugs.
May 01, 2026 · 6 articles
Business
Novo Nordisk: Novo Nordisk is identified as a key competitor in the obesity therapeutics market, facing new challenges from triple-agonist developments.
Eli Lilly and Company: Eli Lilly and Company's retatrutide is highlighted as a leading triple-agonist candidate, signaling its strong position in the evolving obesity therapeutics market.
May 08, 2026 · 6 articles
Business
Novo Nordisk: Novo Nordisk partnered with Emcure Pharma to expand the distribution and marketing of its weight-loss drug semaglutide in India under the brand Poviztra, aiming to reach a wider population.
Eli Lilly and Company: Eli Lilly and Company is a competitor in the Indian weight-loss drug market with its product Mounjaro, which has seen greater uptake than Novo Nordisk's Wegovy.
Nov 10, 2025 · 6 articles
Regulatory
Novo Nordisk: Novo Nordisk received United States — Food and Drug Administration approval for its Wegovy pill, gaining an edge in the obesity treatment market over Eli Lilly and Company. The company expects the pill to be available within weeks, with a starting dose of $149 per month.
Dec 22, 2025 · 23 articles
NEWSDESK
Explore this relationship live
Track how Novo Nordisk and Eli Lilly and Company interact across events, view sentiment trends, and discover connected entities.
Open Dashboard